Search

Your search keyword '"Rhodes, C.J."' showing total 10 results
Start Over Author "Rhodes, C.J." Publication Year Range Last 10 years
10 results on '"Rhodes, C.J."'

2. Integrative Multiomics in the Lung Reveals a Protective Role of Asporin in Pulmonary Arterial Hypertension

Author

Hong, J., primary, Medzikovic, L., additional, Sun, W., additional, Ruffenach, G., additional, Wong, B., additional, Rhodes, C.J., additional, Brownstein, A.J., additional, Liang, L., additional, Aryan, L., additional, Li, M., additional, Vadgama, A., additional, Kurt, Z., additional, Schwantes-An, T.-H., additional, Mickler, E., additional, Gräf, S., additional, Eyries, M., additional, Lutz, K., additional, Pauciulo, M., additional, Trembath, R., additional, Perros, F., additional, Montani, D., additional, Morrell, N., additional, Soubrier, F., additional, Wilkins, M.R., additional, Nichols, W.C., additional, Aldred, M., additional, Desai, A.A., additional, Trégouët, D.-A., additional, Saggar, R., additional, Channick, R.N., additional, Tuder, R.M., additional, Geraci, M.W., additional, Stearman, R., additional, Yang, X., additional, and Eghbali, M., additional

Published
2024
Full Text
View/download PDF

3. SOX17 Enhancer Variants Disrupt Transcription Factor Binding and Enhancer Inactivity Drives Pulmonary Hypertension

Author

Walters, R., primary, Vasilaki, E., additional, Aman, J., additional, Chen, C.-N., additional, Wu, Y., additional, Liang, O., additional, Ashek, A., additional, Dubois, O., additional, Zhao, L., additional, Sabrin, F., additional, Cebola, I., additional, Ferrer, J., additional, Morrell, N.W., additional, Klinger, J.R., additional, Wilkins, M., additional, and Rhodes, C.J., additional

Published
2023
Full Text
View/download PDF

4. Associations Between Serum Activin A and Follistatine-Like 3 Levels and Outcomes in Pulmonary Arterial Hypertension

Author

Guignabert, C., primary, Savale, L., additional, Boucly, A., additional, Thuillet, R., additional, Tu, L., additional, Ottaviani, M., additional, Rhodes, C.J., additional, De Groote, P., additional, Prévot, G., additional, Bergot, E., additional, Bourdin, A., additional, Howard, L., additional, Fadel, E., additional, Beurnier, A., additional, Roche, A., additional, Jevnikar, M., additional, Jaïs, X., additional, Montani, D., additional, Wilkins, M., additional, Sitbon, O., additional, and Humbert, M.J.C., additional

Published
2023
Full Text
View/download PDF

5. Cytokines as Prognostic Biomarkers in Pulmonary Arterial Hypertension

Author

Boucly, A., primary, Tu, L., additional, Guignabert, C., additional, Rhodes, C.J., additional, De Groote, P., additional, Prevot, G., additional, Bergot, E., additional, Bourdin, A., additional, Beurnier, A., additional, Roche, A., additional, Jevnikar, M., additional, Jais, X., additional, Montani, D., additional, Wilkins, M., additional, Humbert, M.J.C., additional, Sitbon, O., additional, and Savale, L., additional

Published
2023
Full Text
View/download PDF

6. Unsupervised Clustering of PH Using Circulating miRNA - Towards Molecular Classification of PH?

Author

Errington, N., primary, Kariotis, S., additional, Jammeh, E., additional, Fong, Y.-L., additional, Lihan, Z., additional, Chen, H., additional, Jatkoe, T., additional, Bridges, C., additional, Vener, T., additional, Wharton, J., additional, Thompson, R., additional, Toshner, M., additional, Howard, L.S., additional, Rhodes, C.J., additional, Wilkins, M., additional, Wang, D., additional, and Lawrie, A., additional

Published
2022
Full Text
View/download PDF

7. Longitudinal Analysis of Three Major Risk-Associated Transcriptomic Subgroups Within the IPAH Classification

Author

Kariotis, S., primary, Jammeh, E., additional, Swietlik, E.M., additional, Rhodes, C.J., additional, Errington, N., additional, Thompson, R., additional, Wharton, J., additional, Coghlan, G., additional, Lordan, J., additional, Corris, P., additional, Howard, L.S., additional, Condliffe, R.A., additional, Kiely, D., additional, Church, A.C., additional, Pepke-Zaba, J., additional, Toshner, M., additional, Wort, J., additional, Gräf, S., additional, Morrell, N.W., additional, Wilkins, M., additional, Wang, D., additional, and Lawrie, A., additional

Published
2022
Full Text
View/download PDF

10. Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study

Author

Rhodes, C.J., Wharton, J., Ghataorhe, P., Watson, G., Girerd, B., Howard, L.S., Gibbs, J.S.R., Condliffe, R., Elliot, C.A., Kiely, D.G., Simonneau, G., Montani, D., Sitbon, O., Gall, H., Schermuly, R.T., Ghofrani, H.A., Lawrie, A., Humbert, M., Wilkins, M.R., Imperial College Healthcare NHS Trust, National Institute for Health Research, British Heart Foundation, Wellcome Trust, and Medical Research Council (MRC)

Subjects
EXPRESSION, Adult, Male, Proteomics, Proteome, Hypertension, Pulmonary, Respiratory System, BIOMARKERS, DIAGNOSIS, Risk Assessment, 1117 Public Health and Health Services, Cohort Studies, PREDICTING SURVIVAL, Critical Care Medicine, Risk Factors, General & Internal Medicine, Humans, Arterial Pressure, Familial Primary Pulmonary Hypertension, Aged, Science & Technology, IDENTIFICATION, RECEPTOR, Gene Expression Profiling, 1103 Clinical Sciences, Blood Proteins, Articles, Middle Aged, ST2, Hypertension, Female, Life Sciences & Biomedicine, 1199 Other Medical and Health Sciences
Abstract

Summary Background Idiopathic and heritable pulmonary arterial hypertension form a rare but molecularly heterogeneous disease group. We aimed to measure and validate differences in plasma concentrations of proteins that are associated with survival in patients with idiopathic or heritable pulmonary arterial hypertension to improve risk stratification. Methods In this observational cohort study, we enrolled patients with idiopathic or heritable pulmonary arterial hypertension from London (UK; cohorts 1 and 2), Giessen (Germany; cohort 3), and Paris (France; cohort 4). Blood samples were collected at routine clinical appointment visits, clinical data were collected within 30 days of blood sampling, and biochemical data were collected within 7 days of blood sampling. We used an aptamer-based assay of 1129 plasma proteins, and patient clinical details were concealed to the technicians. We identified a panel of prognostic proteins, confirmed with alternative targeted assays, which we evaluated against the established prognostic risk equation for pulmonary arterial hypertension derived from the REVEAL registry. All-cause mortality was the primary endpoint. Findings 20 proteins differentiated survivors and non-survivors in 143 consecutive patients with idiopathic or heritable pulmonary arterial hypertension with 2 years' follow-up (cohort 1) and in a further 75 patients with 2·5 years' follow-up (cohort 2). Nine proteins were both prognostic independent of plasma NT-proBNP concentrations and confirmed by targeted assays. The functions of these proteins relate to myocardial stress, inflammation, pulmonary vascular cellular dysfunction and structural dysregulation, iron status, and coagulation. A cutoff-based score using the panel of nine proteins provided prognostic information independent of the REVEAL equation, improving the C statistic from area under the curve 0·83 (for REVEAL risk score, 95% CI 0·77–0·89; p

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results